GlassScriptPhysician profile
Michael Brian Shrader
NPI 1619229283
$1,863.73
in general payments reported to CMS, 2019-2025
21 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $123 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.73 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $405.19 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $373.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $357.55 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $157.85 | 2025 | Dupixent |
| Boston Scientific Corporation | $114.47 | 2025 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $53.35 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.95 | 2025 | Xifaxan |
| Ascensia Diabetes Care US INC. | $52.88 | 2025 | |
| Genzyme Corporation | $43.24 | 2025 | |
| Novo Nordisk INC | $35.42 | 2025 | Wegovy |
| Celltrion USA INC. | $32.11 | 2025 | Vegzelma |
| Qol Medical, LLC | $24.22 | 2024 | Sucraid |
| Xeris Pharmaceuticals, INC. | $22.66 | 2025 | Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2025 | |
| Vivus LLC | $20.78 | 2025 | Qsymia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20.61 | 2025 | |
| Recordati_rare_diseases_inc. | $16.22 | 2025 | Isturisa |
| Lilly USA, LLC | $16.15 | 2024 | Omvoh |
| Mannkind Corporation | $15.37 | 2025 | |
| Intercept Pharmaceuticals, INC. | $14.31 | 2025 | |
| Acella Pharmaceuticals, LLC | $13.74 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shrader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.